Donepezil Versus Non-drug Treatment in Alzheimer's Disease.

Phase 3 Recruiting 240 enrolled Assistance Publique - Hôpitaux de Paris France Alzheimer · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation. The aim of this study is to compare the efficiency of the 2 approaches (non-drug versus donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.

Timeline

Start: 2022-02-10
Primary completion: 2026-08
Completion: 2026-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Donepezil	Small molecule	10 mg	Oral

Indications

No indication recorded.